Metabolic reprogramming is an important characteristic of tumor cells. Tumor cells reprogram their metabolic pathways to meet the material, energy and redox force needs for rapid proliferation. Metabolic reprogramming changes the level or type of specific metabolites inside and outside cells, and promotes tumor growth by affecting gene expression, cell state and the tumor microenvironment. Glucose metabolism, glutamine metabolism and lipid metabolism are significant metabolic pathways in tumors. Targeting metabolic reprogramming can significantly inhibit tumor growth and induce apoptosis. Metabolic reprogramming also plays an important role in maintaining the growth advantage of tumor cells and enhancing the chemotherapy tolerance of lung cancer. This review summarizes abnormal changes in the metabolism of glucose, fat and amino acids in lung cancer, and the underlying molecular mechanism, with the aim of providing novel ideas for the prevention, early diagnosis and treatment of lung cancer.
metabolic reprogramminglung cancerScientific Research Program of Tianjin Education Commission2020KJ151This research was supported by a grant from the Scientific Research Program of Tianjin Education Commission (no. 2020KJ151).Introduction
Lung cancer is a disease with high incidence and mortality rates worldwide. At present, the pathogenic factors of lung cancer have not been completely clarified. The most common pathogenic factor of lung cancer is long-term and high-frequency smoking (1). In addition, long-term exposure to carcinogens, air pollution, human immune status, genetic factors and metabolic activities have been associated with lung cancer (2). Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-SCLC (NSCLC). The latter includes lung squamous cell carcinoma, lung adenocarcinoma (LUAD) and large cell cancer, accounting for ~85% of all lung cancer cases (3). Although considerable progress has been achieved in the targeted treatment of lung cancer in recent years, drug resistance, recurrence and metastasis have brought great difficulties (4). At present, surgical resection is still performed for tumors that limit themselves to the primary location, but 80–85% of patients are already in the unresectable stage at early diagnosis (5). In addition, the progress of lung cancer treatment is limited by the adverse reactions of chemotherapeutic drugs, the high resistance rate of targeted drugs and the immune tolerance microenvironment of the tumor. Therefore, novel strategies for lung cancer treatment need to be developed.
Metabolism is the energy and material basis of life activities. Under normal circumstances, metabolism occurs in the body in an orderly manner to ensure physiological functions (6). However, tumor growth is a multi-factor and multi-stage dynamic process. Some studies have shown that the metabolic pattern of tumor cells is different from that of normal cells (7–9). Metabolic change, also called metabolic reprogramming, plays an important role in regulating the occurrence and development of tumors. To meet the needs of rapid proliferation and growth in a tumor microenvironment with poor blood vessels and nutrition, tumor cells undergo metabolic reprogramming to provide energy and raw materials, maintain the steady state of cell redox and regulate intracellular signal transduction (10). However, the mechanisms underlying tumorigenesis and development remain to be elucidated. Various metabolism-related genes serve as oncogenes and tumor suppressor genes (11). It has been shown that oncogenes such as MYC, NF-κB and AKT can regulate the enzymes in the glycolysis and glutaminolysis pathways (12–14). MYC increases the transcription rate of GLUT transporter and hexokinase-2, which enhances glucose uptake and retention (15).
Therefore, the present review summarizes the abnormal changes in the metabolism of glucose, fat and amino acids in lung cancer, and the molecular mechanisms behind them to provide novel ideas for the prevention, early diagnosis and treatment of lung cancer (Fig. 1).
Glucose metabolism
Metabolic reprogramming is an important marker of cancer (16). A number of metabolic pathways in tumor cells change to meet the material, energy and redox force needs for rapid and continuous cell proliferation (17). In the 1920s, Otto Warburg reported that cancer cells consume a large amount of glucose even in the presence of oxygen, and most of this is metabolized into lactic acid. This phenomenon is called aerobic glycolysis or the Warburg effect (18). This process is one of the important metabolic differences between cancer and most normal tissues, and it is also the first tumor metabolic reprogramming process. Under aerobic conditions, normal cells consume oxygen through glycolysis, the tricarboxylic acid (TCA) cycle and oxidative phosphorylation, thus completely decomposing the glucose and producing a large amount of ATP (34 mol ATP/mol glucose). Under anaerobic conditions, the lack of oxygen prevents the complete degradation of intracellular glucose. Glucose is partially degraded to pyruvate and converted to lactic acid. The energy generated by this process (2 mol ATP/mol glucose) is much lower than that generated by oxidative phosphorylation (19). Although enhanced glycolysis in lung cancer consumes a large amount of glucose and leads to lactic acid accumulation, high levels of glucose have also been found in the serum samples of patients with lung cancer. Although glycolysis accelerates the decomposition of glucose, several reactions in the glycolytic pathway are reversible and participate in glucose resynthesis. Gluconeogenesis, carbohydrate metabolism and lipogenesis can store and provide energy by synthesizing glucose, which may be the reason for the increase in glucose level in lung cancer (20).
Tumor cells produce intermediate metabolites through glycolysis. These intermediate metabolites provide raw materials for biosynthetic pathways, such as nucleotides, lipids, amino acids and reduced nicotinamide adenine dinucleotide phosphate (NADPH), to meet the needs of rapid cell proliferation (21). These metabolic pathways include the pentose phosphate pathway for the production of RNA and NADPH, the hexosamine pathway for protein glycosylation and glycogen production, and the serine biosynthesis pathway (22–24).
The first step in glycolysis is glucose entering the cell through the plasma membrane. Glucose transporters (GLUTs) are important carrier proteins responsible for transporting glucose. Treatment of A549 lung cancer cells with WZB117, an irreversible inhibitor of GLUT1, reduces GLUT1 expression and glucose uptake; it also inhibits the growth of lung cancer cells in cooperation with cisplatin and paclitaxel. The addition of exogenous ATP alleviates this inhibitory effect, which indicates that the inhibition of GLUT1 prevents tumor growth by blocking ATP synthesis (25).
After glucose enters the cell, the first irreversible reaction is the production of glucose-6-phosphate catalyzed by hexokinase 2 (HK2). Tumor cells promote glucose metabolism by increasing glucose uptake and inducing high HK2 expression (26). Targeting HK can reverse the drug resistance of tumor cells (27). 2-Deoxy-D-glucose (2-DG) is a small-molecule inhibitor targeting HK. 2-DG combined with Adriamycin or paclitaxel can significantly delay tumor growth and prolong the survival time of mice with NSCLC (28). Moreover, inhibition of glycolysis by 2-DG can improve the sensitivity of NSCLC with T790M secondary drug resistance mutation to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) (29).
In the second step, fructose-1,6-diphosphate is catalyzed by phosphofructokinase 1 (PFK1). Fascin promotes the transcription of PFKFB3 by promoting the binding of YAP1 to a TEAD1/4 binding site, which activates the expression of PFK1 and mediates glycolysis in lung cancer (30). Not only is PFK expression upregulated in malignant tumors, platelet-type PFK can also regulate the glycolysis level of lung cancer and promote cell proliferation (31).
In the third step, pyruvate kinase catalyzes the conversion of phosphoenolpyruvic acid and ADP to pyruvate and ATP, respectively. Low-affinity pyruvate kinase M2 (PKM2) is highly expressed in lung cancer, and its upregulation is often associated with the hypomethylation of the PKM2 gene promoter. Silencing PKM2 can improve the sensitivity of lung cancer to the chemotherapy drugs cisplatin and docetaxel by increasing apoptosis and inhibiting proliferation. PKM2 is a potential adjuvant therapeutic target (32,33). However, PKM1 rather than PKM2 shows tumor-promoting function in pulmonary neuroendocrine tumors, including SCLC. This finding challenges the view that PKM2 limiting glucose metabolism is a prerequisite for tumorigenesis and provides a theoretical basis for PKM1 as a therapeutic target in SCLC (34).
The attenuation of the last reaction step promotes the entry of intermediate metabolites into the above biosynthetic pathway (35). However, the expression of lactate dehydrogenase (LDH) in lung cancer cells is upregulated (36), which can convert pyruvate into lactate. In addition, lactate secretion is increased, which is characterized by a high expression of monocarboxylate transporter (MCT), as lactate retained in cells inhibits the expression of PFK1 (37). Lactate secretion into the environment can also promote the development of tumors (38). Lactate, as a signal transduction substance under hypoxia, activates the signal pathway associated with tumor cell survival (39). Targeted lactate production is a possible strategy to overcome tumor drug resistance. Inhibition of LDH activity by small interfering RNA or oxalate can overcome the drug resistance of tumor cells to paclitaxel and trastuzumab (40,41). In mice and patients with lung cancer, lactate in tissues and circulation provides an equivalent carbon source for the aerobic oxidation of normal and tumor tissues, and its contribution to mitochondrial metabolism is no less than that of glucose (38,42). Faubert et al (42) injected 13C-labeled lactate into patients with lung cancer and found that lactate can be used as the carbon source of the TCA cycle in patients with different lung cancer types, and that the expression levels of MCT1, MCT4, LDHA and LDHB in tumors are upregulated. In the transplanted tumor model of human lung cancer cells in mice, the levels of isotopic-labeled lactic acid and isotopic-labeled TCA cycle intermediate metabolites at the tumor site are increased. Knockout of MCT1 in mice could reduce the uptake of lactic acid by tumors (43).
The upregulated expression of these key glycolytic enzymes in lung cancer cells is often closely associated with the abnormally activated oncogenes and cancer-promoting signaling pathways in cells. Hypoxia inducible factor-1α (HIF-1α) is an important transcription factor involved in glycolysis regulation in cells, which can directly transcribe and regulate the expression of multiple key glycolysis enzymes (44). The expression of aldolase A in the glycolysis pathway is increased in NSCLC, which consequently increases lactate activity to inhibit prolyl hydroxylase activity and further induce HIF-1α (45). The positive feedback of lactate further promotes the aerobic glycolysis of tumor cells. MYC is an important oncogene that promotes the glycolysis of lung cancer cells by transcriptionally regulating the expression of multiple key glycolytic enzymes (46).
Amino acid metabolism
Amino acid metabolic abnormalities include those in glutamine, serine and glycine, among others, the most important of which are the glutamine metabolic abnormalities (47). In addition to glycolysis, numerous tumor cells also rely on glutamine to meet their bioenergy and metabolic needs. Although glutamine is an important non-essential amino acid required for cell proliferation, it is also an essential amino acid under specific circumstances (48). Glutamine depends on glutamine metabolism, provides metabolic energy for rapidly proliferating tumor cells, provides carbon and nitrogen sources for the synthesis and metabolism of substances, such as nucleotides, amino acids and fatty acids, and maintains the balance and stability of cellular reactive oxygen species (49). Therefore, similar to glucose, glutamine is considered the main nutrient to promote tumor proliferation.
In tumor cells, glutamine can be transported into cells by amino acid transporters as a substrate. Glutamine is then converted into glutamate in the mitochondria and enters the TCA cycle. Some amino acid transporters, such as alanine-serine-cysteine transporter 2, amino acid transporter B0,+ and Human L-type amino acid transporter 1, are overexpressed in lung cancer and upregulate the intake of glutamine by cancer cells (50). Meanwhile, glutamine and glutamate play important roles in the growth of pC9/IR-resistant cells. The growth of erlotinib-resistant NSCLC depends on glutamine (51).
Clinical studies have found high plasma glutamine levels in patients with malignant tumors (52). Glutamine can be converted into glutamate under the action of glutaminase (GLS) for the synthesis of fatty acids and glutathione. Antioxidant glutathione maintains the balance of redox reaction in tumor cells, helps tumor cells resist oxidative stress and prolongs tumor cell survival (53).
GLS is the starting and rate-limiting enzyme for glutamine catabolism (54); it can be divided into renal GLS1 and hepatic GLS2. Selective cleavage of GLS1 precursor mRNA produces two subtypes, glutaminase C (GAC) and renal glutaminase (KGA), which have different regulatory activities (55,56). Some studies have shown that the expression of GAC increases in various types of cancer, such as breast cancer (57), lung cancer (58) and acute myeloid leukemia (59), suggesting that GLS1 is closely associated with glutamine metabolism reprogramming in various tumors.
Van den Heuvel et al(60) analyzed the GAC/KGA ratio in 45 NSCLC tissues and matched normal lung cancer tissues. The study found that the ratio increases significantly in lung cancer tissues, indicating that GAC plays a key role in tumor metabolism. Transfection of the oncogene KRAS induces the dependence of cells on glutamine. However, different KRAS mutation sites may play different roles. For example, lung cancer cells carrying KRAS-G21V mutation are less glutamine-dependent than G12C or G12D mutant cells (60). Recent studies have shown that KRAS and LKB1 co-mutants lead to the invasion and metastasis of NSCLC, accompanied by metabolic reprogramming (61).
Lipid metabolism
Lipids contain thousands of different types of molecules, including glycerophosphingolipids, glycerides, fatty acids, sphingolipids, sterol lipids, pregnenolone lipids, glycolipids and polyketones. Lipids are widely distributed in organelles and are a key component of all membranes (62). Lipid metabolism provides energy for tumor cells, cell proliferation and signaling molecule generation (63).
Fatty acid metabolism and lung cancer
In normal cells, the de novo synthesis of fatty acids generally occurs only in specific tissues, such as liver tissue, adipose tissue and breast tissue during lactation (64). Rapidly proliferating cells increase fatty acid synthesis, provide lipids for membrane components, and are conducive to β-oxidation and protein acyl modification. Therefore, increased fat synthesis is extremely important for highly proliferating cancer cells. When the glucose level is low, tumor cells absorb fatty acids in the surrounding environment for fatty acid metabolism, produce metabolic intermediates, and then enter the TCA cycle to produce ATP and nutrients required for tumor growth (65). Fatty acids are usually stored in lipid droplets in the form of triglycerides (TGs), and free fatty acids are released through the action of adipose TG lipase, hormone-sensitive lipase and monoacylglycerol lipase.
The biosynthesis of fatty acids begins with acetyl-CoA carboxylase (ACC) carboxylating acetyl CoA in the cytoplasm to produce malonyl CoA. Silencing ACC accelerates the growth of lung cancer cells by promoting the redox balance of NADPH (53). ND-646, an allosteric inhibitor of ACC, also exerts an antitumor effect on NSCLC cells (66).
Fatty acid synthase (FASN) catalyzes the assembly of malonyl CoA or acetyl CoA into fatty acids; it is also one of the key enzymes in fatty acid anabolism. The increase in fatty acid synthesis is due to the increase in FASN level, which is closely associated with a poor prognosis, as confirmed in various tumors, such as pancreatic and breast cancer (67,68). Currie et al (69) found a high expression level of fatty acid synthase in NSCLC. A high expression level of FASN not only promotes the growth of tumor cells but also improves the metastatic ability of NSCLC cells and cisplatin resistance (70). Ali et al (71) found that the palmitoylation of EGFR is specifically expressed in mutated EGFR NSCLC with acquired TKI resistance. Mutated EGFR activates FASN mediated by sterol regulatory element-binding proteins (SREBPs), which consequently promote the palmitoylation of EGFR. To produce TKI resistance, orlistat, a selective inhibitor of FASN, can inhibit this effect. Therefore, FASN is an attractive therapeutic target. Most tumor cells rely on the FASN-mediated de novo synthesis of fatty acids, whereas most non-tumor cells rely on exogenous fatty acids. The first targeted drug of FASN, TVB-2640, has entered clinical trials. Combined with paclitaxel, it can stabilize the disease progression in the medium and long term (72,73).
Fatty acid synthesis can also be performed through reductive carboxylation. Glutamine-derived α-ketoglutarate is catalyzed by isocitrate dehydrogenase (IDH) to form citric acid (49). IDH mutations are associated with various tumor types, including gliomas, myeloid malignancies and myelodysplastic syndormes (74). Genetic hybridization of IDH2 mutant mice with carcinogenic FLT3 or NRAS alleles can promote leukemia transformation by inhibiting myeloid cell differentiation (75). The expression levels of FASN, ACC and ATP-citrate lyase (ACLY) are upregulated in fatty acid synthesis in various cancer types, including prostate cancer, breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, pancreatic cancer, gastric cancer and multiple myeloma. Inhibition of these enzymes prevents tumor growth in vitro and in vivo (76–78).
ACLY is the most critical enzyme in glucose catabolism, and cholesterol and fatty acid anabolism. In the presence of ATP and CoA, it catalyzes citric acid in the cytoplasm to produce acetyl CoA and oxaloacetate. Acetyl CoA is not only an important raw material for the de novo synthesis of cholesterol and fatty acids, but also a substrate for protein acetylation modification. ACLY knockdown or inhibition with SB-204990 changes the metabolic pathway to reduce the occurrence of mouse tumors and the formation of transplanted human tumor cells (79,80). Acetylation of 540, 546 and 554 lysine residues (3K) of ACLY polypeptide chain promotes lipid biosynthesis and tumor growth. The acetylation level of ACLY is significantly increased in lung cancer tissues (81). Further investigations have confirmed that ACLY 3K is also a ubiquitin modification site, and a competitive association exists between them. Under high-glucose conditions, P300/calcium-binding protein-associated factor acetyltransferase is activated to promote ACLY acetylation, block ACLY ubiquitination and degradation, improve its stability, and promote de novo lipid synthesis and tumor growth (81). ACLY is a promising therapeutic target for lung cancer; its product, acetyl CoA, is not only an important metabolite, but also a substrate for the acetylation of proteins and nucleic acids. Therefore, inhibiting its production affects de novo fatty acid biosynthesis.
Fatty acids entering the bioactive pool must be activated by acetyl CoA synthetase (ACS) to produce fatty acid CoA. Bioactive fatty acids contribute to protein palmitoylation, a post-translational modification that is particularly important in certain tumors (82). Triacsin C, a chemical inhibitor of ACS, induces the apoptosis of lung cancer cells, and the expression of ACS is negatively correlated with the overall survival of patients with lung cancer (83).
The polyunsaturated fatty acid metabolism and biotransformation pathways have a great impact on tumor apoptosis and proliferation. A number of tumor cells highly express clyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450. These enzymes transform ω-6 polyunsaturated fatty acids into highly active arachidonic acid (AA) to regulate the proliferation and apoptosis of tumor cells (84). Various ω-3 metabolites of polyunsaturated fatty acids inhibit tumorigenic pathways; for example, the eicosapentaenoic acid metabolite ω-3,17,18-epoxide cascade activates anti-proliferation and pro-apoptosis pathways (85). Resolvins produced by LOX metabolites are effective inhibitors of tumor-derived inflammatory pathways (86). The cytosolic phospholipase A2-AA-COX-2 pathway is an important signaling pathway of inflammation, and some key factors of the pathway are associated with lung cancer. Overexpression of COX-2 initiates and promotes lung cancer development (87,88).
Cholesterol metabolism and lung cancer
Cholesterol homeostasis is strictly regulated by a complex protein grid, including its intake, synthesis, efflux, metabolism and esterification. High levels of cholesterol are found in prostate, breast, liver, gastric, colorectal and lung cancer (89,90).
3-Hydroxy-3-methyl glutaryl CoA reductase is the rate-limiting enzyme of cholesterol biosynthesis; it is upregulated in lung cancer and the target of statins regulating plasma cholesterol (91).
In a number of tissues and organs, cholesterol can be converted to 27-hydroxycholersterol (27HC) through sterol 27 hydroxylase (CYP27A1). 27HC is the most abundant hydroxyl cholesterol substance in the circulating blood; its role in cancer mainly depends on the properties of endogenous SREBP and the function of liver X receptor (LXR) regulator.
In normal cells, the rate of cholesterol production is low, occurring through the transcriptional regulation of key genes involved in lipid biosynthesis. Tumor cells can regulate and activate SREBP through the PI3K/Akt/mTOR, MAPK/ERK1/2, HIF-1α, p53 and SHH pathways to increase the signal activity of growth factors or steroid hormone receptors (92). In vivo, 27HC inhibits cholesterol synthesis by regulating SREBP (93).
LXRs are members of the nuclear receptor family of ligand-dependent transcription factors. Activation of LXRs affects cancer progression in various ways. Specifically, LXRs inhibit the proliferation, migration and invasion of breast, prostate, ovarian, lung, skin and colorectal cancer cells (94,95). 27HC is a risk factor for a number of cancer types; it triggers a tumor response to endocrine therapy and reduces the activation of estrogen receptor (ER) to promote angiogenesis, proliferation, invasion and migration (96). By contrast, 27HC inhibits cell viability, proliferation, invasion and migration by activating LXRs in EGFR-mutated malignant tumors, such as lung cancer and colon cancer (97,98). Lung cancer tissues are rich in 27HC, and the expression of 27HC synthase CYP27A1 in lung cancer cells is also higher than that in normal lung cells. 27HC may be the main source of lung cancer occurrence and development (99). Existing research results show that 27HC promotes lung cancer cells proliferation in an ERβ-dependent manner. The role of 27HC is not affected by the membrane-bound ER G protein-coupled receptor 30. Conversely, the role of 27HC is not associated with the activation of EGFR or MAPK, but is mediated by the PI3K/Akt signaling pathway. In other respects, 27HC promotes the production of osteoclasts in the microenvironment of LUAD by inhibiting the expression of miR-139 and activating the STAT3/c-Fos/NFATc1 pathway to accelerate bone metastasis (100). A high-cholesterol diet upregulates the level of 27HC in vivo, whereas 27HC downregulates the cholesterol level of ER-negative NSCLC A549 cells by activating the LXR signaling pathway, and inhibits the activity and proliferation of A549 cells.
Cholesterol is also involved in the drug resistance of tumor cells. For example, Chen et al (101) observed that the cholesterol level is significantly higher in the lipid raft of gefitinib-resistant cells than in that of gefitinib-sensitive cells in NSCLC. After depletion of lipid raft cholesterol, the cells recover their sensitivity to gefitinib. Colenemine and betulin improve the sensitivity of patients with NSCLC to gefitinib by inhibiting SREBP/SCAP or SREBP (102).
Conclusion
Carcinogenesis is a complex process involving multiple genes and steps. In cell carcinogenesis, the imbalance in cell metabolism is not only an important biochemical basis for maintaining various malignant phenotypes, such as tumor cell growth, proliferation and apoptosis, but also a result of the imbalance of the intracellular regulation grid; it involves the activation of oncogenes, the inactivation of tumor suppressor genes and gene mutations. With the continuous development of metabolomics, genomics, proteomics and other associated disciplines and technologies, great breakthroughs have been achieved in the research into the metabolic reprogramming of lung cancer in recent years, and the molecular mechanisms underlying metabolic reprogramming have been gradually understood. However, tumor metabolic reprogramming includes different metabolic pathways that usually involve several regulatory genes, metabolic enzymes and signaling pathways. The research progress associated with lung cancer metabolism is far less than expected, and each metabolic pathway and its specific regulatory mechanism need to be further studied. The identification of the specific metabolic enzymes or metabolites involved in the occurrence and development of lung cancer, and the elucidation of their roles and mechanisms in tumorigenesis warrant further investigation.
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
XL was responsible for the conception of the manuscript, and ML was responsible for consulting relevant literature and manuscript drafting. JC and HL are responsible for designing and overseeing the study, and reviewing the manuscript. All authors read and approved the final manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesTammemagiMCBergCDRileyTLCunninghamCRTaylorKLImpact of lung cancer screening results on smoking cessationJ Natl Cancer Inst106dju084201410.1093/jnci/dju084SunSSchillerJHGazdarAFLung cancer in never smokers-a different diseaseNat Rev Cancer7778790200710.1038/nrc219017882278RelliVTrerotolaMGuerraEAlbertiSAbandoning the notion of non-small cell lung cancerTrends Mol Med25585594201910.1016/j.molmed.2019.04.01231155338ZhengHZhanYLiuSLuJLuoJFengJFanSThe roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implicationsJ Exp Clin Cancer Res37226201810.1186/s13046-018-0901-530217217FernandezYViescaMArvanitakisMEarly diagnosis and management of malignant distal biliary obstruction: A review on current recommendations and guidelinesClin Exp Gastroenterol12415432201910.2147/CEG.S195714MurphyRMWattMJFebbraioMAMetabolic communication during exerciseNat Metab2805816202010.1038/s42255-020-0258-x32747791Gururaja RaoSMitochondrial changes in cancerHandb Exp Pharmacol240211227201710.1007/164_2016_40ChenYChenZFengJHChenYBLiaoNSSuYZouCYMetabolic profiling of normal hepatocyte and hepatocellular carcinoma cells via 1H nuclear magnetic resonance spectroscopyCell Biol Int42425434201810.1002/cbin.10911GuppyMThe hypoxic core: A possible answer to the cancer paradoxBiochem Biophys Res Commun299676680200210.1016/S0006-291X(02)02710-912459193KalyanaramanBTeaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolismRedox Biol12833842201710.1016/j.redox.2017.04.018LevineAJPuzio-KuterAMThe control of the metabolic switch in cancers by oncogenes and tumor suppressor genesScience33013401344201010.1126/science.119349421127244StineZEWaltonZEAltmanBJHsiehALDangCVMYC, metabolism, and cancerCancer Discov510241039201510.1158/2159-8290.CD-15-050726382145MorettiMBennettJTornatoreLThotakuraAKFranzosoGCancer: NF-κB regulates energy metabolismInt J Biochem Cell Biol4422382243201210.1016/j.biocel.2012.08.002CourtnayRNgoDCMalikNVerverisKTortorellaSMKaragiannisTCCancer metabolism and the Warburg effect: The role of HIF-1 and PI3KMol Biol Rep42841851201510.1007/s11033-015-3858-x25689954ChristofkHRVander HeidenMGHarrisMHRamanathanAGersztenREWeiRFlemingMDSchreiberSLCantleyLCThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growthNature452230233200810.1038/nature0673418337823WardPSThompsonCBMetabolic reprogramming: A cancer hallmark even warburg did not anticipateCancer Cell21297308201210.1016/j.ccr.2012.02.014PavlovaNNThompsonCBThe emerging hallmarks of cancer metabolismCell Metab232747201610.1016/j.cmet.2015.12.00626771115LibertiMVLocasaleJWThe warburg effect: How does it benefit cancer cells?Trends Biochem Sci41211218201610.1016/j.tibs.2016.01.004NagaoAKobayashiMKoyasuSChowCCTHaradaHHIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significanceInt J Mol Sci20238201910.3390/ijms20020238MusharrafSGMazharSChoudharyMIRiziNAtta-ur-RahmanPlasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometrySci Rep58607201510.1038/srep0860725712604Vander HeidenMGCantleyLCThompsonCBUnderstanding the Warburg effect: The metabolic requirements of cell proliferationScience32410291033200910.1126/science.116080919460998PatraKCHayNThe pentose phosphate pathway and cancerTrends Biochem Sci39347354201410.1016/j.tibs.2014.06.005LamCLowJYTranPTWangHThe hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategiesCancer Lett5031118202110.1016/j.canlet.2021.01.010AmelioICutruzzolaFAntonovAAgostiniMMelinoGSerine and glycine metabolism in cancerTrends Biochem Sci39191198201410.1016/j.tibs.2014.02.004LiuYCaoYZhangWBergmeierSQianYAkbarHColvinRDingJTongLWuSA small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivoMol Cancer Ther1116721682201210.1158/1535-7163.MCT-12-013122689530XuSHerschmanHRA tumor agnostic therapeutic strategy for hexokinase 1-Null/Hexokinase 2-positive cancersCancer Res7959075914201910.1158/0008-5472.CAN-19-178931434645ZhangXYZhangMCongQZhangMXZhangMYLuYYXuCJHexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagyInt J Biochem Cell Biol95916201810.1016/j.biocel.2017.12.010MaschekGSavarajNPriebeWBraunschweigerPHamiltonKTidmarshGFDe YoungLRLampidisTJ2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res643134200410.1158/0008-5472.CAN-03-329414729604KimSMYunMRHongYKSolcaFKimJHKimHJChoBCGlycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activationMol Cancer Ther1221452156201310.1158/1535-7163.MCT-12-118823883584LinSLiYWangDHuangCMarinoDBolltOWuCTaylorMDLiWDeNicolaGMFascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expressionCancer Lett518230242202110.1016/j.canlet.2021.07.025ShenJJinZLvHJinKJonasKZhuCChenBPFKP is highly expressed in lung cancer and regulates glucose metabolismCell Oncol (Dordr)43617629202010.1007/s13402-020-00508-632219704GuoWZhangYChenTWangYXueJZhangYXiaoWMoXLuYEfficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer modelJ Cancer Res Clin Oncol1376572201110.1007/s00432-010-0860-5ShiHSLiDZhangJWangYSYangLZhangHLWangXHMuBWangWMaYSilencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in miceCancer Sci10114471453201010.1111/j.1349-7006.2010.01562.xMoritaMSatoTNomuraMSakamotoYInoueYTanakaRItoSKurosawaKYamaguchiKSugiuraYPKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growthCancer Cell33355367e7201810.1016/j.ccell.2018.02.004IsraelsenWJVander HeidenMGPyruvate kinase: Function, regulation and role in cancerSemin Cell Dev Biol434351201510.1016/j.semcdb.2015.08.004ZhangXGuoMFanJLvZHuangQHanJWuFHuGXuJJinYPrognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysisCancer Biomark16415423201610.3233/CBM-16058027062698Costa LeiteTDa SilvaDGuimaraes CoelhoRZancanPSola-PennaMLactate favours the dissociation of skeletal muscle 6-phosphofructo-1-kinase tetramers down-regulating the enzyme and muscle glycolysisBiochem J408123130200710.1042/BJ2007068717666012HuiSGhergurovichJMMorscherRJJangCTengXLuWEsparzaLAReyaTLeZhanYanxiang GuoJGlucose feeds the TCA cycle via circulating lactateNature551115118201710.1038/nature2405729045397ColegioORChuNQSzaboALChuTRhebergenAMJairamVCyrusNBrokowskiCEEisenbarthSCPhillipsGMFunctional polarization of tumour-associated macrophages by tumour-derived lactic acidNature513559563201410.1038/nature1349025043024ZhaoYLiuHLiuZDingYLedouxSPWilsonGLVoellmyRLinYLinWNahtaROvercoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolismCancer Res7145854597201110.1158/0008-5472.CAN-11-012721498634ZhouMZhaoYDingYLiuHLiuZFodstadORikerAIKamarajugaddaSLuJOwenLBWarburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxolMol Cancer933201010.1186/1476-4598-9-3320144215FaubertBLiKYCaiLHensleyCTKimJZachariasLGYangCDoQNDoucetteSBurgueteDLactate metabolism in human lung tumorsCell171358371e9201710.1016/j.cell.2017.09.019HensleyCTFaubertBYuanQLev-CohainNJinEKimJJiangLKoBSkeltonRLoudatLMetabolic heterogeneity in human lung tumorsCell164681694201610.1016/j.cell.2015.12.034XieNTanZBanerjeeSCuiHGeJLiuRMBernardKThannickalVJLiuGGlycolytic reprogramming in myofibroblast differentiation and lung fibrosisAm J Respir Crit Care Med19214621474201510.1164/rccm.201504-0780OC26284610ChangYCChanYCChangWMLinYFYangCJSuCYHuangMSWuATHHsiaoMFeedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progressionCancer Lett4032836201710.1016/j.canlet.2017.06.001RomeroOATorres-DizMProsESavolaSGomezAMoranSSaezCIwakawaRVillanuevaAMontuengaLMMAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1Cancer Discov4292303201410.1158/2159-8290.CD-13-079924362264de KoningTJAmino acid synthesis deficienciesJ Inherit Metab Dis40609620201710.1007/s10545-017-0063-128653176CluntunAALukeyMJCerioneRALocasaleJWGlutamine metabolism in cancer: Understanding the heterogeneityTrends Cancer3169180201710.1016/j.trecan.2017.01.00528393116AltmanBJStineZEDangCVFrom Krebs to clinic: Glutamine metabolism to cancer therapyNat Rev Cancer16773201610.1038/nrc.2016.13128704359ScaliseMPochiniLGalluccioMConsoleLIndiveriCGlutamine transport and mitochondrial metabolism in cancer cell growthFront Oncol7306201710.3389/fonc.2017.00306SerizawaMKusuharaMZangiacomiVUrakamiKWatanabeMTakahashiTYamaguchiKYamamotoNKohYIdentification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cellsAnticancer Res3427792787201424922639DunphyMPSHardingJJVennetiSZhangHBurnaziEMBrombergJOmuroAMHsiehJJMellinghoffIKStatonKIn vivo PET assay of tumor glutamine flux and metabolism: In-Human Trial of 18F-(2S,4R)-4-FluoroglutamineRadiology287667675201810.1148/radiol.201716261029388903JeonSMChandelNSHayNAMPK regulates NADPH homeostasis to promote tumour cell survival during energy stressNature485661665201210.1038/nature1106622660331YuYNewmanHShenLSharmaDHuGMirandoAJZhangHKnudsenEZhangGFHiltonMJKarnerCMGlutamine metabolism regulates proliferation and lineage allocation in skeletal stem cellsCell Metab29966978e4201910.1016/j.cmet.2019.01.01630773468SimonJNunez-GarciaMFernandez-TussyPBarbier-TorresLFernández-RamosDGómez-SantosBBuquéXLopitz-OtsoaFGoikoetxea-UsandizagaNSerrano-MaciaMTargeting hepatic glutaminase 1 ameliorates non-alcoholic steatohepatitis by restoring very-low-density lipoprotein triglyceride assemblyCell Metab31605622e10202010.1016/j.cmet.2020.01.01332084378MatesJMCampos-SandovalJAMarquezJGlutaminase isoenzymes in the metabolic therapy of cancerBiochim Biophys Acta Rev Cancer1870158164201810.1016/j.bbcan.2018.07.00730053497DaemenALiuBSongKKwongMGaoMHongRNanniniMPetersonDLiedererBMde la CruzCPan-Cancer metabolic signature predicts co-dependency on glutaminase and de novo glutathione synthesis linked to a high-mesenchymal cell stateCell Metab28383399e389201810.1016/j.cmet.2018.06.00330043751HanTZhanWGanMLiuFYuBChinYEWangJBPhosphorylation of glutaminase by PKCε is essential for its enzymatic activity and critically contributes to tumorigenesisCell Res28655669201810.1038/s41422-018-0021-y29515166JacqueNRonchettiAMLarrueCMeunierGBirsenRWillemsLSalandEDecroocqJMacielTTLambertMTargeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionBlood12613461356201510.1182/blood-2015-01-62187026186940van den HeuvelAPJingJWoosterRFBachmanKEAnalysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growthCancer Biol Ther1311851194201210.4161/cbt.2134822892846KimJLeeHMCaiFKoBYangCLieuELMuhammadNRhyneSLiKHaloulMThe hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancerNat Metab214011412202010.1038/s42255-020-00316-033257855SezginELeventalIMayorSEggelingCThe mystery of membrane organization: Composition, regulation and roles of lipid raftsNat Rev Mol Cell Biol18361374201710.1038/nrm.2017.16SnaebjornssonMTJanaki-RamanSSchulzeAGreasing the wheels of the cancer machine: The role of lipid metabolism in cancerCell Metab316276202010.1016/j.cmet.2019.11.01031813823MenendezJALupuRFatty acid synthase and the lipogenic phenotype in cancer pathogenesisNat Rev Cancer7763777200710.1038/nrc222217882277CorbetCFeronOCancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fuelingBiochim Biophys Acta Rev Cancer1868715201710.1016/j.bbcan.2017.01.00228110019SvenssonRUParkerSJEichnerLJKolarMJWallaceMBrunSNLombardoPSVan NostrandJLHutchinsAVeraLInhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical modelsNat Med2211081119201610.1038/nm.418127643638TadrosSShuklaSKKingRJGundaVVernucciEAbregoJChaikaNVYuFLazenbyAJBerimLDe novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancerCancer Res7755035517201710.1158/0008-5472.CAN-16-306228811332BuckleyDDukeGHeuerTSO'FarrellMWagmanASMcCullochWKembleGFatty acid synthase-Modern tumor cell biology insights into a classical oncology targetPharmacol Ther1772331201710.1016/j.pharmthera.2017.02.02128202364CurrieESchulzeAZechnerRWaltherTCFareseRVJrCellular fatty acid metabolism and cancerCell Metab18153161201310.1016/j.cmet.2013.05.01723791484ShenMTsaiYZhuRKengPCChenYChenYLeeSOFASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cellsBiochim Biophys Acta Mol Cell Biol Lipids1863313322201810.1016/j.bbalip.2017.12.01229306075AliALevantiniETeoJTGoggiJClohessyJGWuCSChenLYangHKrishnanIKocherOFatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancerEMBO Mol Med10e8313201810.15252/emmm.20170831329449326FalchookGInfanteJArkenauHTPatelMRDeanEBorazanciEBrennerACookNLopezJPantSFirst-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumorsEClinicalMedicine34100797202110.1016/j.eclinm.2021.10079733870151JonesSFInfanteJRMolecular pathways: Fatty acid synthaseClin Cancer Res2154345438201510.1158/1078-0432.CCR-15-012626519059DangLYenKAttarECIDH mutations in cancer and progress toward development of targeted therapeuticsAnn Oncol27599608201610.1093/annonc/mdw013ChenCLiuYLuCCrossJRMorris JPIVShroffASWardPSBradnerJEThompsonCLoweSWCancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionGenes Dev2719741985201310.1101/gad.226613.11324065765MigitaTNaritaTNomuraKMiyagiEInazukaFMatsuuraMUshijimaMMashimaTSeimiyaHSatohYATP citrate lyase: Activation and therapeutic implications in non-small cell lung cancerCancer Res6885478554200810.1158/0008-5472.CAN-08-123518922930ChajesVCambotMMoreauKLenoirGMJoulinVAcetyl-CoA carboxylase alpha is essential to breast cancer cell survivalCancer Res6652875294200610.1158/0008-5472.CAN-05-148916707454CarrerATrefelySZhaoSCampbellSLNorgardRJSchultzKCSidoliSParrisJLDAffrontiHCSivanandSAcetyl-CoA metabolism supports multistep pancreatic tumorigenesisCancer Discov9416435201910.1158/2159-8290.CD-18-056730626590ZaidiNSwinnenJVSmansKATP-citrate lyase: A key player in cancer metabolismCancer Res7237093714201210.1158/0008-5472.CAN-11-411222787121HatzivassiliouGZhaoFBauerDEAndreadisCShawANDhanakDHingoraniSRTuvesonDAThompsonCBATP citrate lyase inhibition can suppress tumor cell growthCancer Cell8311321200510.1016/j.ccr.2005.09.008LinRTaoRGaoXLiTZhouXGuanKLXiongYLeiQYAcetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growthMol Cell51506518201310.1016/j.molcel.2013.07.002NiuJSunYChenBZhengBJarugumilliGKWalkerSRHataANMino-KenudsonMFrankDAWuXFatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylationNature573139143201910.1038/s41586-019-1511-x31462771MashimaTOh-haraTSatoSMochizukiMSugimotoYYamazakiKHamadaJTadaMMoriuchiTIshikawaYp53-defective tumors with a functional apoptosome-mediated pathway: A new therapeutic targetJ Natl Cancer Inst97765777200510.1093/jnci/dji133YarlaNSBishayeeASethiGReddannaPKalleAMDhananjayaBLDowluruKSChintalaRDuddukuriGRTargeting arachidonic acid pathway by natural products for cancer prevention and therapySemin Cancer Biol40–414881201610.1016/j.semcancer.2016.02.001MurrayMHraikiABebawyMPazderkaCRawlingTAnti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugsPharmacol Ther150109128201510.1016/j.pharmthera.2015.01.00825603423VannitambyASaadMIAloeCWangHKumarBVlahosRSelemidisSIrvingLSteinfortDJenkinsBJBozinovskiSAspirin-triggered resolvin D1 reduces proliferation and the neutrophil to lymphocyte ratio in a mutant KRAS-driven lung adenocarcinoma modelCancers (Basel)133224202110.3390/cancers1313322434203378RiedlKKrysanKPoldMDalwadiHHeuze-Vourc'hNDohadwalaMLiuMCuiXFiglinRMaoJTMultifaceted roles of cyclooxygenase-2 in lung cancerDrug Resist Updat7169184200410.1016/j.drup.2004.04.003XinCChuLZhangLGengDWangYSunDSuiPZhaoXGongZSuiMZhangWExpression of cytosolic phospholipase A2 (cPLA2)-arachidonic acid (AA)-Cyclooxygenase-2 (COX-2) pathway factors in lung cancer patients and its implication in lung cancer early detection and prognosisMed Sci Monit2555435551201910.12659/MSM.915314YueSLiJLeeSYLeeHJShaoTSongBChengLMastersonTALiuXRatliffTLChengJXCholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressivenessCell Metab19393406201410.1016/j.cmet.2014.01.01924606897KopeckaJTrouillasPGasparovicACGazzanoEAssarafYGRigantiCPhospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targetsDrug Resist Updat49100670202010.1016/j.drup.2019.100670YeganehBWiechecEAndeSRSharmaPMoghadamARPostMFreedDHHashemiMShojaeiSZekiAAGhavamiSTargeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary diseasePharmacol Ther14387110201410.1016/j.pharmthera.2014.02.00724582968GorinAGabitovaLAstsaturovIRegulation of cholesterol biosynthesis and cancer signalingCurr Opin Pharmacol12710716201210.1016/j.coph.2012.06.011LiDLongWHuangRChenYXiaM27-Hydroxycholesterol inhibits sterol regulatory element-binding protein 1 activation and hepatic lipid accumulation in miceObesity (Silver Spring)26713722201810.1002/oby.2213029476609NelsonERWardellSEJasperJSParkSSuchindranSHoweMKCarverNJPillaiRVSullivanPMSondhiV27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiologyScience34210941098201310.1126/science.124190824288332WangBTontonozPLiver X receptors in lipid signalling and membrane homeostasisNat Rev Endocrinol14452463201810.1038/s41574-018-0037-xGibsonDACollinsFCousinsFLEsnal ZufiaurreASaundersPTKThe impact of 27-hydroxycholesterol on endometrial cancer proliferationEndocr Relat Cancer25381391201810.1530/ERC-17-044929371332WuYYuDDHuYCaoHXYuSRLiuSWFengJFLXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activationBiochem Biophys Res Commun467900905201510.1016/j.bbrc.2015.10.04726471306Lo SassoGBovengaFMurzilliSSalvatoreLDi TullioGMartelliND'OrazioARainaldiSVaccaMMangiaALiver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in miceGastroenterology144149715071507e113201310.1053/j.gastro.2013.02.00523419360HiramitsuSIshikawaTLeeWRKhanTCrumbleyCKhwajaNZamanianFAsghariASenMZhangYEstrogen receptor beta-mediated modulation of lung cancer cell proliferation by 27-hydroxycholesterolFront Endocrinol (Lausanne)9470201810.3389/fendo.2018.0047030190703ZhangLLiuMLiuJLiXYangMSuBLinY27-Hydroxycholesterol enhanced osteoclastogenesis in lung adenocarcinoma microenvironmentJ Cell Physiol2341269212700201910.1002/jcp.27883ChenQPanZZhaoMWangQQiaoCMiaoLDingXHigh cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancerJ Cell Physiol23367226732201810.1002/jcp.26351LiJYanHZhaoLJiaWYangHLiuLZhouXMiaoPSunXSongSInhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cellsOncotarget75239252403201610.18632/oncotarget.10721
Tumor metabolism in lung cancer. An overview of key metabolic pathways and their associated crucial molecules in lung cancer cells is presented. Red arrows represent upregulated genes or metabolites involved in tumor metabolism, and the developed inhibitors are indicated. GLUT1, glucose transporter 1; HK2, hexokinase 2; G6P, glucose-6-phosphate; PFK1, phosphofructokinase 1; PEP, phosphoenolpyruvic acid; PKM2, pyruvate kinase M2; MCT, monocarboxylate transporter; LDH, lactate dehydrogenase; FA, fatty acid; FASN, fatty acid synthase; ACC, acetyl-CoA carboxylase; ACLY, ATP-citrate lyase; GAC, glutaminase C; ASCT2, alanine-serine-cysteine transporter 2; ATB0+, amino acid transporter B0,+; LAT1, Human L-type amino acid transporter 1; α-KG, α-ketoglutarate; OAA, oxaloacetate; PDH, pyruvate dehydrogenase; GLS, glutaminase; KGA, kidney-type glutaminase.